Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
NCT ID NCT07718737
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This trial is testing an experimental drug called AMT-116 in people with advanced or metastatic non-squamous non-small cell lung cancer that has worsened after standard treatments. The study has two parts: the first compares two different doses of AMT-116 to see which works better and is safer; the second compares the chosen dose against standard chemotherapy options. Participants receive treatment every two weeks as long as they benefit and can tolerate it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental antibody-drug conjugate called AMT-116
- What this could lead to
- If successful, AMT-116 could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
- What could go wrong
- This is an early-to-mid-stage trial, so AMT-116 may not prove more effective or safer than existing treatments. Side effects are possible, and the optimal dose is still being determined.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health (Olivia Newton John Cancer Centre)
Melbourne, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Calvary Mater Newcastle
Newcastle, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Coffs Harbour Health Campus
Coffs Harbour, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Macquarie University Hospital
Sydney, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St Vincent's Hospital Melbourne
Melbourne, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy
- New combo aims to stall lung cancer when targeted pills start to fail
- New hope for lung cancer patients: drug combo targets tough tumors
- New hope for lung cancer: experimental drug combo enters trial